Literature DB >> 32157692

The role of integrins in melanoma: a review.

Suzette M Arias-Mejias1,2, Katerina Y Warda1, Enrica Quattrocchi1, Hector Alonso-Quinones2, Sindhuja Sominidi-Damodaran1, Alexander Meves1.   

Abstract

Integrins are the major family of cell adhesion receptors in humans and essential for a wide range of normal physiology, including formation and maintenance of tissue structure integrity, cell migration, proliferation, and differentiation. Integrins also play a prominent role in tumor growth and metastasis. Translational research has tried to define the contribution of integrins to the phenotypic aggressiveness of melanoma because such knowledge is clinically useful. For example, differential expression of integrins in primary cutaneous melanoma can be used to distinguish indolent from aggressive, prometastatic melanoma. Recent studies have shown that gene expression-based testing of patient-derived melanoma tissue is feasible, and molecular tests may fully replace interventional surgical methods such as sentinel lymph node biopsies in the future. Because of their central role in mediating invasion and metastasis, integrins are likely to be useful biomarkers. Integrins are also attractive candidate targets for interventional therapy. This article focuses on the role of integrins in melanoma and highlights recent advances in the field of translational research.
© 2020 the International Society of Dermatology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32157692      PMCID: PMC7167356          DOI: 10.1111/ijd.14850

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  82 in total

1.  Multivesicular bodies.

Authors:  Michael J Clague; Sylvie Urbé
Journal:  Curr Biol       Date:  2008-05-20       Impact factor: 10.834

2.  Altered integrin expression patterns shown by microarray in human cutaneous melanoma.

Authors:  Laura Vizkeleti; Timea Kiss; Viktoria Koroknai; Szilvia Ecsedi; Orsolya Papp; Istvan Szasz; Roza Adany; Margit Balazs
Journal:  Melanoma Res       Date:  2017-06       Impact factor: 3.599

3.  Distinct structural requirements for binding of the integrins alphavbeta6, alphavbeta3, alphavbeta5, alpha5beta1 and alpha9beta1 to osteopontin.

Authors:  Yasuyuki Yokosaki; Kumi Tanaka; Fumiko Higashikawa; Keisuke Yamashita; Akira Eboshida
Journal:  Matrix Biol       Date:  2005-09       Impact factor: 11.583

4.  Expression of the alpha7beta1 laminin receptor suppresses melanoma growth and metastatic potential.

Authors:  B L Ziober; Y Q Chen; D M Ramos; N Waleh; R H Kramer
Journal:  Cell Growth Differ       Date:  1999-07

Review 5.  Integrins in cancer: biological implications and therapeutic opportunities.

Authors:  Jay S Desgrosellier; David A Cheresh
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

6.  Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression.

Authors:  S M Albelda; S A Mette; D E Elder; R Stewart; L Damjanovich; M Herlyn; C A Buck
Journal:  Cancer Res       Date:  1990-10-15       Impact factor: 12.701

7.  Role of integrin alpha 2 beta 1 (VLA-2) in the migration of human melanoma cells on laminin and type IV collagen.

Authors:  T Etoh; L Thomas; C Pastel-Levy; R B Colvin; M C Mihm; H R Byers
Journal:  J Invest Dermatol       Date:  1993-05       Impact factor: 8.551

8.  Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

Authors:  Roger Stupp; Monika E Hegi; Thierry Gorlia; Sara C Erridge; James Perry; Yong-Kil Hong; Kenneth D Aldape; Benoit Lhermitte; Torsten Pietsch; Danica Grujicic; Joachim Peter Steinbach; Wolfgang Wick; Rafał Tarnawski; Do-Hyun Nam; Peter Hau; Astrid Weyerbrock; Martin J B Taphoorn; Chiung-Chyi Shen; Nalini Rao; László Thurzo; Ulrich Herrlinger; Tejpal Gupta; Rolf-Dieter Kortmann; Krystyna Adamska; Catherine McBain; Alba A Brandes; Joerg Christian Tonn; Oliver Schnell; Thomas Wiegel; Chae-Yong Kim; Louis Burt Nabors; David A Reardon; Martin J van den Bent; Christine Hicking; Andriy Markivskyy; Martin Picard; Michael Weller
Journal:  Lancet Oncol       Date:  2014-08-19       Impact factor: 41.316

Review 9.  Clinical Application of Radiolabeled RGD Peptides for PET Imaging of Integrin αvβ3.

Authors:  Haojun Chen; Gang Niu; Hua Wu; Xiaoyuan Chen
Journal:  Theranostics       Date:  2016-01-01       Impact factor: 11.556

Review 10.  Integrins as Therapeutic Targets: Successes and Cancers.

Authors:  Sabine Raab-Westphal; John F Marshall; Simon L Goodman
Journal:  Cancers (Basel)       Date:  2017-08-23       Impact factor: 6.639

View more
  7 in total

1.  PD-1, PD-L1, and BIM as Predictors of Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.

Authors:  Felix F Kung; Suzette M Arias-Mejias; Enrica Quattrocchi; Sindhuja Sominidi-Damodaran; Alina G Bridges; Julia S Lehman; Amy L Weaver; Alexander Meves
Journal:  J Invest Dermatol       Date:  2020-04-08       Impact factor: 8.551

2.  β3 integrin immunohistochemistry as a method to predict sentinel lymph node status in patients with primary cutaneous melanoma.

Authors:  Enrica Quattrocchi; Sindhuja Sominidi-Damodaran; Dennis H Murphree; Alexander Meves
Journal:  Int J Dermatol       Date:  2020-08-09       Impact factor: 2.736

Review 3.  Integrin Regulators in Neutrophils.

Authors:  Sunitha Pulikkot; Liang Hu; Yunfeng Chen; Hao Sun; Zhichao Fan
Journal:  Cells       Date:  2022-06-25       Impact factor: 7.666

4.  Gene Expression Patterns of Osteopontin Isoforms and Integrins in Malignant Melanoma.

Authors:  Krisztina Jámbor; Viktória Koroknai; Tímea Kiss; István Szász; Péter Pikó; Margit Balázs
Journal:  Pathol Oncol Res       Date:  2022-08-24       Impact factor: 2.874

5.  Bioinformatic Analysis Identifies Potential Key Genes in the Pathogenesis of Melanoma.

Authors:  Yanjie Han; Xinxin Li; Jiliang Yan; Chunyan Ma; Xin Wang; Hong Pan; Xiaoli Zheng; Zhen Zhang; Biao Gao; Xin-Ying Ji
Journal:  Front Oncol       Date:  2020-10-16       Impact factor: 6.244

Review 6.  Acidic and Hypoxic Microenvironment in Melanoma: Impact of Tumour Exosomes on Disease Progression.

Authors:  Zaira Boussadia; Adriana Rosa Gambardella; Fabrizio Mattei; Isabella Parolini
Journal:  Cells       Date:  2021-11-25       Impact factor: 6.600

7.  Primary cutaneous melanoma risk stratification using a clinicopathologic and gene expression model: a pilot study.

Authors:  Suzette M Arias-Mejias; Enrica Quattrocchi; Dennie Tempel; Mark Luna-Vargas; Jeff Chen; Dennis H Murphree; Sandra Gjorgova Gjeorgjievski; Julia S Lehman; Alina G Bridges; Jvalini Dwarkasing; Alexander Meves
Journal:  Int J Dermatol       Date:  2020-06-09       Impact factor: 3.204

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.